Update

Page 1 of 2  > >>

May 28, 2010
QuantiBact Inc. participated at ASM, American Society for Microbiology, 110th General Meeting, San Diego May 23-27th.
May 7, 2010
QuantiBact, Inc. has filed a new patent on the TINA-based Cliffhanger® PCR technology
Jan 20, 2010
QuantiBact Inc. has chosen Mr. Palle Schelde as the CEO.
 


"Improving Nature"


QuantiBact is developing a technology that will significantly improve molecular diagnostics in the near future.

QuantiBact is a biotech company founded on research regarding nucleic acid analogues performed at The University of Southern Denmark and Hvidovre Hospital.

We are developing diagnostic tools for the detection of infectious diseases by: increasing specificity, minimizing turn-around time and increasing fidelity of quantification. Our technology will significantly improve hybridization and PCR based assays.